Tocilizumab-induced hyperbilirubinemia in Japanese patients with rheumatoid arthritis: its association with UDP glucuronosyltransferase 1A1 gene polymorphisms

References

• Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford). 2010;49: 15–24.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol. 2008 (181):151–60.
   Google Scholar
• Hushaw LL, Sawaqed R, Sweis G, Reigle J, Gopal A, Brandt D, et al. Critical appraisal of tocilizumab in the treatment of mod-erate to severe rheumatoid arthritis. Ther Clin Risk Manag. 2010;6:143–52.
   PubMed Web of Science ®Google Scholar
• Mircic M, Kavanaugh A. The clinical efficacy of tocilizumab in rheumatoid arthritis. Drugs Today (Bare). 2009;45:189–97.
   PubMedGoogle Scholar
• Patel AM, Moreland LW. Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Des Dev Ther. 2010;4:263–78.
   PubMed Web of Science ®Google Scholar
• Mori S, Ueki Y. Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab. Mod Rheumatol. 2011 (Epub ahead of print).
   Google Scholar
• Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs. 2009;69: 609–32.
   Google Scholar
• Hennigan S, Kavanaugh A. Interleukin-6 inhibitors in the treat-ment of rheumatoid arthritis. Ther Clin Risk Manag. 2008;4: 767–75.
   PubMedGoogle Scholar
• Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817–29.
   PubMed Web of Science ®Google Scholar
• Bosma PJ, Seppen J, Goldhoorn B, Bakker C, Oude Elferink RP, Chowdhury JR, et al. Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem. 1994;269:17960–4.
   PubMed Web of Science ®Google Scholar
• Strassburg CP. Pharmacogenetics of Gilbert's syndrome. Phar-macogenomics. 2008;9:703–15.
   Google Scholar
• Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene pro-moter and Gilbert's syndrome. Lancet. 1996;347:578–81.
   Google Scholar
• Aono S, Adachi Y, Uyama E, Yamada Y, Keino H, Nanno T, et al. Analysis of genes for bilirubin UDP-glucuronosyltransfer-ase in Gilbert's syndrome. Lancet. 1995;345:958–9.
   PubMed Web of Science ®Google Scholar
• Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 1995;333:1171–5.
   PubMed Web of Science ®Google Scholar
• Koiwai 0, Nishizawa M, Hasada K, Aono S, Adachi Y, Mamiya N, et al. Gilbert's syndrome is caused by a heterozygous missense mutation in the gene for bilirubin UDP-glucuronosyltransferase. Hum Mol Genet. 1995;4:1183–6.
   Google Scholar
• Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics. 2007;17:497–504.
   PubMed Web of Science ®Google Scholar
• Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer. 2004;91: 678–82.
   Google Scholar
• Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irino-tecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000;60: 6921–6.
   PubMed Web of Science ®Google Scholar
• Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22:1382–8.
   PubMed Web of Science ®Google Scholar
• Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol. 1998;9:845–7.
   PubMed Web of Science ®Google Scholar
• Iyer L, Das S, Janisch L, Wen M, Ramirez J, Kanison T, et al. UGT1A1*28 polymorphism as a determinant of irinotecan dis-position and toxicity. Pharmacogenomics J. 2002;2:43–7.
   PubMedGoogle Scholar
• Rotger M, Taffe P, Bleiber G, Gunthard HF, Furrer H, Vernazza P, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis. 2005;192: 1381–6.
   PubMed Web of Science ®Google Scholar
• Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humph-reys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos. 2005;33:1729–39.
   Google Scholar
• Rouits E, Boisdron-Celle M, Dumont A, Guerin 0, Morel A, Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res. 2004;10: 5151–9.
   Google Scholar
• Ando Y, Chida M, Nakayama K, Saka H, Kamataki T. The UGT1A1*28 allele is relatively rare in a Japanese population. Pharmacogenetics. 1998;8: 357–60.
   Google Scholar
• Takeuchi K, Kobayashi Y, Tamaki S, Ishihara T, Maruo Y, Araki J, et al. Genetic polymorphisms of bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese patients with Crigler-Najjar syndrome or Gilbert's syndrome as well as in healthy Japanese subjects. J Gastroenterol Hepatol. 2004;19: 1023–8.
   PubMed Web of Science ®Google Scholar
• Akaba K, Kimura T, Sasaki A, Tanabe S, Wakabayashi T, Hiroi M, et al. Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese. J Hum Genet. 1999;44:22–5.
   PubMed Web of Science ®Google Scholar
• Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA. 1998;95: 8170–4.
   Google Scholar
• Saito A, Kawamoto M, Kamatani N. Association study between single-nucleotide polymorphisms in 199 drug-related genes and commonly measured quantitative traits of 752 healthy Japanese subjects. J Hum Genet. 2009;54: 317–23.
   Google Scholar
• Strassburg CP, Manns MP. Jaundice, genes and promoters. J Hepatol. 2000;33:476–9.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Alexander GJ. Gilbert's syndrome: an overview for clinical biochemists. Ann Clin Biochem. 2006;43:340–3.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tanaka Y, Amano K, Hoshi D, Nawata M, Nagas-awa H et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients—REACTION 52-week study. Rheumatology (Oxford). 2011;50:1908–15.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Ha-nami K, et al. Efficacy and tolerability of tocilizumab in rheu-matoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol. 2011;21:122–33.
   Google Scholar
• Kuehl GE, Lampe JW, Potter JD, Bigler J. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005;33:1027–35.
   PubMed Web of Science ®Google Scholar
• Strasser SI, Mashford ML, Desmond PV. Regulation of uridine diphosphate glucuronosyltransferase during the acute-phase response. J Gastroenterol Hepatol. 1998;13:88–94.
   Google Scholar
• Monshouwer M, Witkamp RF, Nujmeijer SM, Van Amsterdam JG, Van Miert AS. Suppression of cytochrome P450- and UDP glucuronosyl transferase-dependent enzyme activities by proin-flammatory cytokines and possible role of nitric oxide in primary cultures of pig hepatocytes. Toxicol Appl Pharmacol. 1996;137: 237–44.
   Google Scholar
• Vee ML, Lecureur V, Stieger B, Fardel 0. Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or inter-leukin-6. Drug Metab Dispos. 2009;37: 685–93.
   Google Scholar
• Lankisch TO, Schulz C, Zwingers T, Erichsen TJ, Manns MP, He-inemann V, et al. Gilbert's Syndrome and irinotecan toxicity: com-bination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol Biomarkers Prey. 2008;17: 695–701.
   Google Scholar
• Lankisch TO, Moebius U, Wehmeier M, Behrens G, Manns MP, Schmidt RE, et al. Gilbert's disease and atazanavir: from phe-notype to UDP-glucuronosyltransferase haplotype. Hepatology. 2006;44:1324–32.
   PubMed Web of Science ®Google Scholar
• Lee JS, Wang J, Martin M, Germer S, Kenwright A, Benayed R, et al. Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab. Pharmacogenet Genomics. 2011;21: 365–74.
   PubMedGoogle Scholar
• Biason P, Masier S, Toffofi G. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity. J Chemo-ther. 2008;20: 158–65.
   Google Scholar